Performance of three different anticitrullinated protein/peptide tests for predicting the total, erosion, and joint space narrowing Sharp scores. Patients were stratified according to baseline RF status
| 5 Year Sharp score | Antibody status at baseline | OR (95% CI) | Sensitivity | Specificity | PPV | NPV | |
|---|---|---|---|---|---|---|---|
| OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; CCP, cyclic citrullinated peptides; APF, antiperinuclear factor; AKA, antikeratin antibody; RF, rheumatoid factor; +, positive; −, negative. | |||||||
| Total | RF+ | CCP+ | 2.3 (1 to 5.5) | 67 | 54 | 61 | 59 |
| APF+ | 3.0 (1.3 to 7.2) | 60 | 67 | 67 | 59 | ||
| AKA+ | 1.2 (0.5 to 2.7) | 35 | 68 | 51 | 52 | ||
| RF− | CCP+ | 2.1 (0.5 to 8.3) | 65 | 53 | 65 | 53 | |
| APF+ | 1.4 (0.4 to 5.4) | 53 | 56 | 59 | 50 | ||
| AKA+ | 1.3 (0.3 to 5.4) | 40 | 67 | 61 | 45 | ||
| Erosions | RF+ | CCP+ | 2.5 (0.9 to 6.8) | 72 | 49 | 37 | 81 |
| APF+ | 3.5 (1.3 to 9.2) | 61 | 68 | 48 | 78 | ||
| AKA+ | 0.6 (0.2 to 1.6) | 26 | 63 | 21 | 69 | ||
| RF− | CCP+ | 1.8 (0.4 to 7.8) | 67 | 55 | 40 | 73 | |
| APF+ | 0.7 (0.2 to 2.7) | 42 | 48 | 29 | 61 | ||
| AKA+ | 2.3 (0.5 to 9.6) | 50 | 69 | 44 | 73 | ||
| Joint space narrowing | RF+ | CCP+ | 2.2 (0.9 to 5.3) | 68 | 52 | 53 | 67 |
| APF+ | 3.3 (1.4 to 7.7) | 63 | 65 | 60 | 68 | ||
| AKA+ | 1.6 (0.7 to 3.8) | 40 | 71 | 51 | 61 | ||
| RF− | CCP+ | 1.1 (0.3 to 4.4) | 59 | 44 | 50 | 53 | |
| APF+ | 1.4 (0.4 to 5.3) | 53 | 55 | 53 | 55 | ||
| AKA+ | 2.3 (0.6 to 9.4) | 48 | 72 | 61 | 59 | ||